|
Gene: ASGR2 |
Gene summary for ASGR2 |
Gene summary. |
Gene information | Species | Human | Gene symbol | ASGR2 | Gene ID | 433 |
Gene name | asialoglycoprotein receptor 2 | |
Gene Alias | ASGP-R2 | |
Cytomap | 17p13.1 | |
Gene Type | protein-coding | GO ID | GO:0001503 | UniProtAcc | P07307 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
433 | ASGR2 | NAFLD1 | Human | Liver | NAFLD | 2.41e-03 | 3.52e-01 | -0.04 |
433 | ASGR2 | S43 | Human | Liver | Cirrhotic | 2.32e-14 | -3.04e-01 | -0.0187 |
433 | ASGR2 | HCC1_Meng | Human | Liver | HCC | 2.64e-71 | 2.96e-01 | 0.0246 |
433 | ASGR2 | HCC2_Meng | Human | Liver | HCC | 2.07e-20 | -5.16e-01 | 0.0107 |
433 | ASGR2 | cirrhotic1 | Human | Liver | Cirrhotic | 4.31e-12 | 4.56e-01 | 0.0202 |
433 | ASGR2 | cirrhotic2 | Human | Liver | Cirrhotic | 5.30e-05 | 2.51e-01 | 0.0201 |
433 | ASGR2 | HCC1 | Human | Liver | HCC | 1.09e-04 | 4.47e+00 | 0.5336 |
433 | ASGR2 | HCC2 | Human | Liver | HCC | 1.63e-24 | 4.86e+00 | 0.5341 |
433 | ASGR2 | HCC5 | Human | Liver | HCC | 5.26e-03 | 2.22e+00 | 0.4932 |
433 | ASGR2 | Pt13.b | Human | Liver | HCC | 3.61e-08 | -8.04e-02 | 0.0251 |
433 | ASGR2 | S014 | Human | Liver | HCC | 1.67e-21 | 1.67e+00 | 0.2254 |
433 | ASGR2 | S015 | Human | Liver | HCC | 3.04e-27 | 2.66e+00 | 0.2375 |
433 | ASGR2 | S016 | Human | Liver | HCC | 1.63e-29 | 1.94e+00 | 0.2243 |
433 | ASGR2 | S027 | Human | Liver | HCC | 4.92e-10 | 1.21e+00 | 0.2446 |
433 | ASGR2 | S028 | Human | Liver | HCC | 1.27e-24 | 1.57e+00 | 0.2503 |
433 | ASGR2 | S029 | Human | Liver | HCC | 1.52e-27 | 1.89e+00 | 0.2581 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Liver | HCC: Hepatocellular carcinoma | |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00550883 | Liver | NAFLD | lipid homeostasis | 44/1882 | 167/18723 | 1.48e-09 | 2.54e-07 | 44 |
GO:00316477 | Liver | NAFLD | regulation of protein stability | 61/1882 | 298/18723 | 5.00e-08 | 4.71e-06 | 61 |
GO:003164712 | Liver | Cirrhotic | regulation of protein stability | 144/4634 | 298/18723 | 6.74e-19 | 1.28e-16 | 144 |
GO:005508811 | Liver | Cirrhotic | lipid homeostasis | 74/4634 | 167/18723 | 2.46e-08 | 8.51e-07 | 74 |
GO:00015035 | Liver | Cirrhotic | ossification | 127/4634 | 408/18723 | 1.89e-03 | 1.19e-02 | 127 |
GO:003164722 | Liver | HCC | regulation of protein stability | 211/7958 | 298/18723 | 2.29e-23 | 5.01e-21 | 211 |
GO:00550882 | Liver | HCC | lipid homeostasis | 103/7958 | 167/18723 | 4.27e-07 | 7.18e-06 | 103 |
GO:0009100 | Liver | HCC | glycoprotein metabolic process | 193/7958 | 387/18723 | 1.89e-03 | 9.62e-03 | 193 |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ASGR2 | SNV | Missense_Mutation | novel | c.575N>G | p.Ser192Cys | p.S192C | P07307 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AC-A5XS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD |
ASGR2 | SNV | Missense_Mutation | novel | c.16N>G | p.Gln6Glu | p.Q6E | P07307 | protein_coding | tolerated(0.32) | benign(0.115) | TCGA-BH-A2L8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | CR |
ASGR2 | SNV | Missense_Mutation | c.820G>A | p.Gly274Arg | p.G274R | P07307 | protein_coding | deleterious(0.04) | probably_damaging(0.995) | TCGA-AA-3710-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
ASGR2 | SNV | Missense_Mutation | novel | c.766N>C | p.Tyr256His | p.Y256H | P07307 | protein_coding | deleterious(0) | possibly_damaging(0.793) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
ASGR2 | SNV | Missense_Mutation | c.214G>A | p.Val72Met | p.V72M | P07307 | protein_coding | deleterious(0.01) | probably_damaging(0.996) | TCGA-CM-5861-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
ASGR2 | SNV | Missense_Mutation | novel | c.715N>T | p.Asp239Tyr | p.D239Y | P07307 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
ASGR2 | SNV | Missense_Mutation | rs575606476 | c.472N>T | p.Arg158Cys | p.R158C | P07307 | protein_coding | deleterious(0) | probably_damaging(0.973) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
ASGR2 | SNV | Missense_Mutation | novel | c.466N>T | p.Asp156Tyr | p.D156Y | P07307 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ASGR2 | SNV | Missense_Mutation | c.242N>A | p.Ser81Asn | p.S81N | P07307 | protein_coding | tolerated(1) | benign(0.015) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
ASGR2 | SNV | Missense_Mutation | novel | c.527G>A | p.Cys176Tyr | p.C176Y | P07307 | protein_coding | deleterious(0.01) | possibly_damaging(0.677) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |